Slingshot members are tracking this event:

EC approves Amgen's IMLYGIC (talimogene laherparepvec) as first oncolytic immunotherapy In Europe. This approval grants a centralized marketing authorization in the 28 countries that are members of the EU

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 17, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Unresectable Melanoma, Metastatic Melanoma, Imlygic, Talimogene Laherparepvec, Oncolytic Immunotherapy, Approval, Marketing Authorization